Federal Agency · National Institutes of Health
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Posted November 22, 2024
Funding
Funding amount not specified
Closes
November 19, 2026
NAICS
541714
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD).
Award details
Applications close on November 19, 2026 (205 days remaining).
Categories
Not categorized
Sign up at GrantRegister to see if this grant matches your organization.
Match my organization →View application on Grants.gov →·Source: Grants.gov·Last seen Apr 28, 2026